Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
ELVN Stock Chart & Stats
$20.10
$0.01(0.04%)
At close: 4:00 PM EST
$20.10
$0.01(0.04%)
Day’s Range― - ―
52-Week Range$13.30 - $30.03
Previous CloseN/A
Volume37.78K
Average Volume (3M)542.25K
Market Cap
$1.22B
Enterprise Value$555.10M
Total Cash (Recent Filing)$490.50M
Total Debt (Recent Filing)$376.00K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 06, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding59,235,546
10 Day Avg. Volume418,914
30 Day Avg. Volume542,255
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue1.76K
Enterprise Value/Gross Profit-7.21K
Enterprise Value/Ebitda-4.87
Forecast
1Y Price Target
$40.50Price Target Upside101.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Efficacy And Safety Of ELVN-001ELVN-001's impressive efficacy and favorable tolerability profile have either remained consistent or improved with longer follow-up, supporting the compound's strong profile.
Financial StabilityEnliven ended the period with $490.5M in cash, cash equivalents, and marketable securities, which is expected to provide runway into H1 2029.
Market PotentialELVN-001 is designed to improve upon prior TKIs for CML with strong proof-of-concept data and a high MMR rate, positioning it to become a standard therapy in this multi-billion dollar market.
Bears Say
Competitive LandscapeELVN-001 could be positioned as a key treatment post-asciminib, which is anticipated to become a multi-billion-dollar treatment across CML lines of therapy.
Dependence On Future TrialsEnliven plans to initiate the pivotal Phase 3 trial in 2026, which shows progress in the development of their treatment.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $13.30 and its highest was $30.03 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $1.22B.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 21 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.537 by $0.047.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.43.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 59,235,546 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.537. Following the earnings report the stock price went down -1.051%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Currently, no hedge funds are holding shares in ELVN
Enliven Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.50 (101.49% Upside)
$40.50 (101.49% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.56%
12-Months-Change
Fundamentals
Return on Equity
-25.26%
Trailing 12-Months
Asset Growth
54.07%
Trailing 12-Months
Company Description
Enliven Therapeutics
Enliven Therapeutics (ELVN) is a biopharmaceutical company dedicated to discovering and developing innovative therapies for patients with serious diseases. The company operates in the healthcare sector, focusing on cutting-edge research and development to bring novel treatments to market. Enliven Therapeutics aims to address unmet medical needs through its pipeline of therapeutic candidates, leveraging advanced scientific approaches to improve patient outcomes.
ELVN Stock 12 Month Forecast
Average Price Target
$40.50
▲(101.49% Upside)
Technical Analysis
Sarepta Therapeutics
―
Viridian Therapeutics
―
Cidara Therapeutics
―
Intellia Therapeutics
―
AbCellera Biologics
―